High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study

MLA

Jun Li, et al. “High Efficacy of Azacitidine plus HAG in Acute Myeloid Leukemia: An Open-Label, Single-Arm, Multi-Center, Phase 2 Study.” Blood Cancer Journal, vol. 12, no. 10, Oct. 2022, pp. 1–5. EBSCOhost, https://doi.org/10.1038/s41408-022-00740-3.

APA

Jun Li, Qi Han, Yanqing Huang, Yanhui Wei, Jie Zi, Lidong Zhao, Zhimei Cai, Xuzhang Lu, Rong Xiao, Yanming Zhang, Xiaotian Yang, Hao Xu, Naitong Sun, Wanchuan Zhuang, Zhengdong Wu, Yuan Xia, Yanli Xu, Bin He, Wei Zhu, … Zheng Ge. (2022). High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study. Blood Cancer Journal, 12(10), 1–5. https://doi.org/10.1038/s41408-022-00740-3

Chicago

Jun Li, Qi Han, Yanqing Huang, Yanhui Wei, Jie Zi, Lidong Zhao, Zhimei Cai, et al. 2022. “High Efficacy of Azacitidine plus HAG in Acute Myeloid Leukemia: An Open-Label, Single-Arm, Multi-Center, Phase 2 Study.” Blood Cancer Journal 12 (10): 1–5. doi:10.1038/s41408-022-00740-3.